Literature DB >> 2525511

Binding of levonorgestrel, norethisterone and desogestrel to human sex hormone binding globulin and influence on free testosterone levels.

B Nilsson1, B von Schoultz.   

Abstract

The progestogens desogestrel, levonorgestrel, lynestrenol and norethisterone are known to display certain androgenic effects. Apart from direct androgen receptor interaction, binding to sex hormone binding globulin (SHBG) and displacement of testosterone could lead to an increase in free, metabolically active testosterone. The affinities for SHBG binding of some progestogens including levonorgestrel, norethisterone and the active metabolite of desogestrel, 3-keto-desogestrel, were compared using an equilibrium partition method, and the distribution between free and protein-bound testosterone during progestogen therapy was calculated with the use of a computer program. During treatment with desogestrel, levonorgestrel and norethisterone alone, testosterone displacement could account for a slight increase in free testosterone, though the decrease in serum SHBG following treatment was found to be more important in this respect. Also during treatment with combinations of ethinyl estradiol and levonorgestrel for oral contraception, testosterone displacement could theoretically have a slight influence on free testosterone levels. Combinations with ethinyl estradiol and desogestrel or norethisterone, on the other hand, cause an increase in SHBG concentration and as a result a fall in free testosterone which could not be compensated via testosterone displacement.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525511     DOI: 10.1159/000293644

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  3 in total

1.  Estimating systemic exposure to levonorgestrel from an oral contraceptive.

Authors:  Cale N Basaraba; Carolyn L Westhoff; Malcolm C Pike; Renu Nandakumar; Serge Cremers
Journal:  Contraception       Date:  2016-12-30       Impact factor: 3.375

2.  Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.

Authors:  Daniel L J Thorek; Anson T Ku; Nicholas Mitsiades; Darren Veach; Philip A Watson; Dipti Metha; Sven-Erik Strand; Sai Kiran Sharma; Jason S Lewis; Diane S Abou; Hans G Lilja; Steven M Larson; Michael R McDevitt; David Ulmert
Journal:  Clin Cancer Res       Date:  2018-09-25       Impact factor: 12.531

3.  Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index.

Authors:  Melissa Natavio; Frank Z Stanczyk; Emilie A G Molins; Anita Nelson; William J Jusko
Journal:  Contraception       Date:  2019-01-28       Impact factor: 3.051

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.